NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Pharmacology NURS 251 | Module 6 Exam
Portage Learning (2026/2027) Actual Questions & Answers with
Rationales
90 CNS Pharmacology Practice Questions with Detailed Rationales | Updated PDF
Cognitive Levels: 35% Recall | 45% Application | 20% Analysis • Format: 70% Scenario-Based, 30% Direct Recall
How to Use This Study Guide: Each question is followed by four options (A-D). The correct option is marked
[CORRECT] in green. A detailed rationale explains the pharmacologic reasoning, including mechanism of action, adverse
effects, therapeutic monitoring, nursing considerations, and patient safety principles — serving double duty as exam practice
and study content. The competency label identifies the NURS 251 Module 6 domain being assessed. Work through all 90
questions, review rationales for both correct and incorrect answers, and revisit sections where you missed multiple questions.
Commonly confused drug pairs (benzodiazepines vs. barbiturates, typical vs. atypical antipsychotics, SSRI vs. SNRI) and
boxed warnings are highlighted throughout for targeted review.
Exam Sections Overview
Section 1: Central Nervous System Pharmacology Foundations (Q1-12)
Section 2: Sedative-Hypnotics and Anxiolytics (Q13-26)
Section 3: Antiepileptic Drugs and Seizure Management (Q27-40)
Section 4: Antipsychotic and Mood-Stabilizing Agents (Q41-54)
Section 5: Antidepressant Pharmacology (Q55-68)
Section 6: Opioid Analgesics and CNS Stimulants (Q69-80)
Section 7: Anesthetics, Muscle Relaxants, and Nursing Safety (Q81-90)
Page 1
,NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Section 1: Central Nervous System Pharmacology Foundations
Neurotransmission, BBB, & CNS Drug Principles | Questions 1-12
Q1: Which structural feature of the blood-brain barrier (BBB) most directly prevents the passage
of water-soluble and polar drugs into the central nervous system?
A. Wide fenestrations in capillary endothelium allowing free diffusion
B. Tight junctions between cerebral capillary endothelial cells, supplemented by astrocyte foot processes,
creating a lipid barrier that excludes hydrophilic molecules [CORRECT]
C. Rapid first-pass metabolism by brain capillary enzymes
D. High concentration of drug efflux transporters in the choroid plexus only
Correct Answer: B
Rationale: The BBB is formed by tight junctions (zonula occludens) between cerebral capillary endothelial cells, with
surrounding astrocyte end-foot processes reinforcing the barrier. This excludes water-soluble, polar, and large molecules from
passive diffusion. Lipid-soluble (lipophilic) drugs cross readily by passive diffusion. Option A describes fenestrated capillaries
found in the choroid plexus and circumventricular organs (no BBB). Option C describes hepatic first-pass effect, not BBB.
Option D describes one component but not the primary barrier. Study tip: lipophilicity × small molecular weight = better BBB
penetration.
Competency: BBB Structure & Function | Cognitive: Recall
Q2: A patient with Parkinson's disease is prescribed levodopa combined with carbidopa.
Carbidopa cannot cross the blood-brain barrier. What is the primary therapeutic rationale for this
combination?
A. Carbidopa enhances dopamine release within the striatum directly
B. Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa breakdown outside the CNS
and increasing the amount of levodopa that crosses the BBB to be converted to dopamine centrally
[CORRECT]
C. Carbidopa directly blocks dopamine receptors in the periphery to reduce side effects
D. Carbidopa crosses the BBB to inhibit central monoamine oxidase
Correct Answer: B
Rationale: Levodopa is the dopamine precursor that crosses the BBB and is converted to dopamine by DOPA decarboxylase
in the striatum. Without carbidopa, ~95% of levodopa is decarboxylated in the periphery, causing dopaminergic side effects
(nausea, arrhythmias, hypotension) and leaving only ~5% to reach the brain. Carbidopa inhibits peripheral DOPA
decarboxylase (does not cross BBB), allowing more levodopa to reach the CNS — reducing required levodopa dose by ~75%
and decreasing peripheral side effects. Options A, C, D mischaracterize carbidopa's mechanism and location. Study tip:
carbidopa = periphery only; levodopa = crosses BBB.
Competency: BBB Drug Application (Levodopa/Carbidopa) | Cognitive: Application
Page 2
,NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Q3: Which neurotransmitter is the primary inhibitory neurotransmitter in the central nervous
system and the molecular target enhanced by benzodiazepines?
A. Glutamate
B. Gamma-aminobutyric acid (GABA) [CORRECT]
C. Acetylcholine
D. Dopamine
Correct Answer: B
Rationale: GABA is the primary inhibitory neurotransmitter in the CNS, present at ~40% of brain synapses.
Benzodiazepines, barbiturates, and many anticonvulsants enhance GABAergic neurotransmission, producing anxiolytic,
sedative, anticonvulsant, and muscle-relaxant effects. Glutamate (option A) is the primary excitatory neurotransmitter.
Acetylcholine (option C) is involved in memory, autonomic function, and neuromuscular transmission. Dopamine (option D)
is involved in movement, reward, and psychiatric disorders. Study tip: GABA = inhibitory (calm); glutamate = excitatory
(activate); the balance between them regulates CNS tone.
Competency: CNS Neurotransmitters | Cognitive: Recall
Q4: A drug with high lipophilicity, low molecular weight, and minimal ionization at physiological
pH is most likely to:
A. Be excluded from the CNS by the blood-brain barrier
B. Readily cross the blood-brain barrier and produce CNS effects [CORRECT]
C. Require active transport across the BBB only
D. Be rapidly degraded by brain enzymes before exerting effects
Correct Answer: B
Rationale: BBB penetration depends on: (1) lipophilicity (lipid-soluble drugs cross readily); (2) molecular weight (small
molecules cross better, < 500 Da preferred); (3) ionization (non-ionized form crosses; ionized form trapped outside); (4)
absence of P-glycoprotein efflux. Drugs meeting these criteria (e.g., lorazepam, morphine, ethanol) cross the BBB readily and
produce CNS effects. Option A applies to water-soluble or large/polar molecules. Option C describes specific transport
systems (e.g., L-DOPA via large neutral amino acid transporter). Option D is not a primary barrier mechanism. Study tip:
predict BBB crossing using "LIPS" — Lipophilic, Ionized (no), Protein binding (low), Small.
Competency: BBB Drug Properties | Cognitive: Application
Page 3
, NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Q5: Which statement accurately describes the mechanism of action of selective serotonin
reuptake inhibitors (SSRIs)?
A. They directly stimulate postsynaptic serotonin receptors
B. They block the presynaptic serotonin transporter (SERT), increasing serotonin concentration in the
synaptic cleft and enhancing serotonergic neurotransmission [CORRECT]
C. They inhibit monoamine oxidase, preventing serotonin breakdown
D. They block serotonin receptors postsynaptically to reduce serotonin activity
Correct Answer: B
Rationale: SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) selectively block the serotonin transporter
(SERT) on the presynaptic neuron, preventing reuptake of serotonin (5-HT) back into the presynaptic terminal. This increases
serotonin concentration and dwell time in the synaptic cleft, enhancing postsynaptic serotonergic neurotransmission.
Therapeutic antidepressant effects develop over 2-6 weeks (vs. immediate synaptic changes) due to downstream receptor
adaptations. Option A describes direct agonists (e.g., buspirone partial agonist at 5-HT1A). Option C describes MAOIs.
Option D describes serotonin antagonists (e.g., cyproheptadine used for serotonin syndrome). Study tip: reuptake inhibitors
raise synaptic neurotransmitter concentration; MAOIs raise intracellular neurotransmitter.
Competency: SSRI Mechanism of Action | Cognitive: Recall
Q6: A nurse is preparing to administer a medication that has a narrow therapeutic index and
significant CNS effects. Which principle should guide administration?
A. The drug has a wide safety margin and can be dosed liberally
B. Therapeutic drug monitoring (TDM) is essential, with dose adjustments based on serum levels to
avoid toxicity while maintaining efficacy [CORRECT]
C. Loading doses are unnecessary because the drug equilibrates quickly
D. The drug's effects are unrelated to serum concentration
Correct Answer: B
Rationale: Narrow therapeutic index (NTI) drugs (e.g., phenytoin, lithium, valproic acid, digoxin, warfarin) have a small
margin between therapeutic and toxic doses. CNS-active NTI drugs require therapeutic drug monitoring (TDM) to maintain
serum levels within the therapeutic range, individualize dosing, and prevent toxicity. Examples: phenytoin 10-20 mcg/mL,
lithium 0.6-1.2 mEq/L (acute), valproic acid 50-100 mcg/mL, carbamazepine 4-12 mcg/mL. Option A is opposite of NTI
principle. Option C may be appropriate for some NTI drugs (loading dose) but not the safety principle. Option D is incorrect;
pharmacologic effect correlates with serum concentration. Study tip: any CNS drug with a target serum level = NTI = TDM
required.
Competency: Narrow Therapeutic Index Drugs | Cognitive: Application
Page 4
Pharmacology NURS 251 | Module 6 Exam
Portage Learning (2026/2027) Actual Questions & Answers with
Rationales
90 CNS Pharmacology Practice Questions with Detailed Rationales | Updated PDF
Cognitive Levels: 35% Recall | 45% Application | 20% Analysis • Format: 70% Scenario-Based, 30% Direct Recall
How to Use This Study Guide: Each question is followed by four options (A-D). The correct option is marked
[CORRECT] in green. A detailed rationale explains the pharmacologic reasoning, including mechanism of action, adverse
effects, therapeutic monitoring, nursing considerations, and patient safety principles — serving double duty as exam practice
and study content. The competency label identifies the NURS 251 Module 6 domain being assessed. Work through all 90
questions, review rationales for both correct and incorrect answers, and revisit sections where you missed multiple questions.
Commonly confused drug pairs (benzodiazepines vs. barbiturates, typical vs. atypical antipsychotics, SSRI vs. SNRI) and
boxed warnings are highlighted throughout for targeted review.
Exam Sections Overview
Section 1: Central Nervous System Pharmacology Foundations (Q1-12)
Section 2: Sedative-Hypnotics and Anxiolytics (Q13-26)
Section 3: Antiepileptic Drugs and Seizure Management (Q27-40)
Section 4: Antipsychotic and Mood-Stabilizing Agents (Q41-54)
Section 5: Antidepressant Pharmacology (Q55-68)
Section 6: Opioid Analgesics and CNS Stimulants (Q69-80)
Section 7: Anesthetics, Muscle Relaxants, and Nursing Safety (Q81-90)
Page 1
,NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Section 1: Central Nervous System Pharmacology Foundations
Neurotransmission, BBB, & CNS Drug Principles | Questions 1-12
Q1: Which structural feature of the blood-brain barrier (BBB) most directly prevents the passage
of water-soluble and polar drugs into the central nervous system?
A. Wide fenestrations in capillary endothelium allowing free diffusion
B. Tight junctions between cerebral capillary endothelial cells, supplemented by astrocyte foot processes,
creating a lipid barrier that excludes hydrophilic molecules [CORRECT]
C. Rapid first-pass metabolism by brain capillary enzymes
D. High concentration of drug efflux transporters in the choroid plexus only
Correct Answer: B
Rationale: The BBB is formed by tight junctions (zonula occludens) between cerebral capillary endothelial cells, with
surrounding astrocyte end-foot processes reinforcing the barrier. This excludes water-soluble, polar, and large molecules from
passive diffusion. Lipid-soluble (lipophilic) drugs cross readily by passive diffusion. Option A describes fenestrated capillaries
found in the choroid plexus and circumventricular organs (no BBB). Option C describes hepatic first-pass effect, not BBB.
Option D describes one component but not the primary barrier. Study tip: lipophilicity × small molecular weight = better BBB
penetration.
Competency: BBB Structure & Function | Cognitive: Recall
Q2: A patient with Parkinson's disease is prescribed levodopa combined with carbidopa.
Carbidopa cannot cross the blood-brain barrier. What is the primary therapeutic rationale for this
combination?
A. Carbidopa enhances dopamine release within the striatum directly
B. Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa breakdown outside the CNS
and increasing the amount of levodopa that crosses the BBB to be converted to dopamine centrally
[CORRECT]
C. Carbidopa directly blocks dopamine receptors in the periphery to reduce side effects
D. Carbidopa crosses the BBB to inhibit central monoamine oxidase
Correct Answer: B
Rationale: Levodopa is the dopamine precursor that crosses the BBB and is converted to dopamine by DOPA decarboxylase
in the striatum. Without carbidopa, ~95% of levodopa is decarboxylated in the periphery, causing dopaminergic side effects
(nausea, arrhythmias, hypotension) and leaving only ~5% to reach the brain. Carbidopa inhibits peripheral DOPA
decarboxylase (does not cross BBB), allowing more levodopa to reach the CNS — reducing required levodopa dose by ~75%
and decreasing peripheral side effects. Options A, C, D mischaracterize carbidopa's mechanism and location. Study tip:
carbidopa = periphery only; levodopa = crosses BBB.
Competency: BBB Drug Application (Levodopa/Carbidopa) | Cognitive: Application
Page 2
,NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Q3: Which neurotransmitter is the primary inhibitory neurotransmitter in the central nervous
system and the molecular target enhanced by benzodiazepines?
A. Glutamate
B. Gamma-aminobutyric acid (GABA) [CORRECT]
C. Acetylcholine
D. Dopamine
Correct Answer: B
Rationale: GABA is the primary inhibitory neurotransmitter in the CNS, present at ~40% of brain synapses.
Benzodiazepines, barbiturates, and many anticonvulsants enhance GABAergic neurotransmission, producing anxiolytic,
sedative, anticonvulsant, and muscle-relaxant effects. Glutamate (option A) is the primary excitatory neurotransmitter.
Acetylcholine (option C) is involved in memory, autonomic function, and neuromuscular transmission. Dopamine (option D)
is involved in movement, reward, and psychiatric disorders. Study tip: GABA = inhibitory (calm); glutamate = excitatory
(activate); the balance between them regulates CNS tone.
Competency: CNS Neurotransmitters | Cognitive: Recall
Q4: A drug with high lipophilicity, low molecular weight, and minimal ionization at physiological
pH is most likely to:
A. Be excluded from the CNS by the blood-brain barrier
B. Readily cross the blood-brain barrier and produce CNS effects [CORRECT]
C. Require active transport across the BBB only
D. Be rapidly degraded by brain enzymes before exerting effects
Correct Answer: B
Rationale: BBB penetration depends on: (1) lipophilicity (lipid-soluble drugs cross readily); (2) molecular weight (small
molecules cross better, < 500 Da preferred); (3) ionization (non-ionized form crosses; ionized form trapped outside); (4)
absence of P-glycoprotein efflux. Drugs meeting these criteria (e.g., lorazepam, morphine, ethanol) cross the BBB readily and
produce CNS effects. Option A applies to water-soluble or large/polar molecules. Option C describes specific transport
systems (e.g., L-DOPA via large neutral amino acid transporter). Option D is not a primary barrier mechanism. Study tip:
predict BBB crossing using "LIPS" — Lipophilic, Ionized (no), Protein binding (low), Small.
Competency: BBB Drug Properties | Cognitive: Application
Page 3
, NURS 251 Module 6 | Pharmacology | Portage Learning (2026/2027) Actual Q&A with Rationales | Updated PDF
Q5: Which statement accurately describes the mechanism of action of selective serotonin
reuptake inhibitors (SSRIs)?
A. They directly stimulate postsynaptic serotonin receptors
B. They block the presynaptic serotonin transporter (SERT), increasing serotonin concentration in the
synaptic cleft and enhancing serotonergic neurotransmission [CORRECT]
C. They inhibit monoamine oxidase, preventing serotonin breakdown
D. They block serotonin receptors postsynaptically to reduce serotonin activity
Correct Answer: B
Rationale: SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) selectively block the serotonin transporter
(SERT) on the presynaptic neuron, preventing reuptake of serotonin (5-HT) back into the presynaptic terminal. This increases
serotonin concentration and dwell time in the synaptic cleft, enhancing postsynaptic serotonergic neurotransmission.
Therapeutic antidepressant effects develop over 2-6 weeks (vs. immediate synaptic changes) due to downstream receptor
adaptations. Option A describes direct agonists (e.g., buspirone partial agonist at 5-HT1A). Option C describes MAOIs.
Option D describes serotonin antagonists (e.g., cyproheptadine used for serotonin syndrome). Study tip: reuptake inhibitors
raise synaptic neurotransmitter concentration; MAOIs raise intracellular neurotransmitter.
Competency: SSRI Mechanism of Action | Cognitive: Recall
Q6: A nurse is preparing to administer a medication that has a narrow therapeutic index and
significant CNS effects. Which principle should guide administration?
A. The drug has a wide safety margin and can be dosed liberally
B. Therapeutic drug monitoring (TDM) is essential, with dose adjustments based on serum levels to
avoid toxicity while maintaining efficacy [CORRECT]
C. Loading doses are unnecessary because the drug equilibrates quickly
D. The drug's effects are unrelated to serum concentration
Correct Answer: B
Rationale: Narrow therapeutic index (NTI) drugs (e.g., phenytoin, lithium, valproic acid, digoxin, warfarin) have a small
margin between therapeutic and toxic doses. CNS-active NTI drugs require therapeutic drug monitoring (TDM) to maintain
serum levels within the therapeutic range, individualize dosing, and prevent toxicity. Examples: phenytoin 10-20 mcg/mL,
lithium 0.6-1.2 mEq/L (acute), valproic acid 50-100 mcg/mL, carbamazepine 4-12 mcg/mL. Option A is opposite of NTI
principle. Option C may be appropriate for some NTI drugs (loading dose) but not the safety principle. Option D is incorrect;
pharmacologic effect correlates with serum concentration. Study tip: any CNS drug with a target serum level = NTI = TDM
required.
Competency: Narrow Therapeutic Index Drugs | Cognitive: Application
Page 4
